Activation of β1 integrins and caveolin-1 by TF/FVIIa promotes IGF-1R signaling and cell survival

Mikael Åberg1 · Desirée Edén1 · Agneta Siegbahn1

Published online: 27 May 2020
© The Author(s) 2020

Abstract
The tissue factor/coagulation factor VIIa (TF/FVIIa) complex induces transactivation of the IGF-1 receptor (IGF-1R) in a number of different cell types. The mechanism is largely unknown. The transactivation leads to protection from apoptosis and nuclear translocation of the IGF-1R. The aim of this study was to clarify the signaling pathway between TF and IGF-1R after FVIIa treatment with PC3 and DU145 prostate or MDA-MB-231 breast cancer cells as model systems. Protein interactions, levels, and phosphorylations were assessed by proximity ligation assay or flow cytometry in intact cells and by western blot on cell lysates. The transactivation of the IGF-1R was found dependent on TF/FVIIa-induced activation of β1-integrins. A series of experiments led to the conclusion that the caveolae protein caveolin-1 prevented IGF-1R activation in resting cells via its scaffolding domain. TF/FVIIa/β1-integrins terminated this inhibition by activation of Src family kinases and subsequent phosphorylation of caveolin-1 on tyrosine 14. This phosphorylation was not seen after treatment with PAR1 or PAR2 agonists. Consequently, the protective effect of FVIIa against apoptosis induced by the death receptor agonist TRAIL and the de novo synthesis of cyclin D1 induced by nuclear IGF-1R accumulation were both significantly reduced by downregulation of β1-integrins or overexpression of the caveolin-1 scaffolding domain. In conclusion, we present a plausible mechanism for the interplay between TF and IGF-1R involving FVIIa, β1-integrins, Src family proteins, and caveolin-1. Our results increase the knowledge of diseases associated with TF and IGF-1R overexpression in general but specifically of TF-mediated signaling with focus on cell survival.

Keywords
Apoptosis · Tissue factor · IGF-1R · Integrins · Caveolin-1

Introduction
Tissue factor (TF) is a 47 kDa transmembrane glycoprotein and the initiator of the humoral coagulation. TF binds and activates its natural ligand coagulation factor VII (FVII) into FVIIa, an event that leads to activation of factor Xa (FXa) and thrombin and subsequently fibrin formation. Extravascular expression of TF provides a hemostatic envelope for protection if a vessel ruptures, whereas the intravascular expression normally is kept very low to avoid excessive clot formation [1]. Both in vitro and in vivo data consequently support a role for aberrant expression of TF in diseases associated with thrombosis such as cardiovascular disorders, diabetes, and cancer [2–4]. The TF/FVIIa complex also activates intracellular signaling pathways in a number of different cell types [5–9]. This implicates important roles for TF in different diseases uncoupled from its role in coagulation, which is exemplified by the high levels of TF found on many types of cancer cells where the signaling abilities of TF facilitates metastasis and spreading of tumors [10–12]. Today it is known that TF signaling can be transduced over the cell surface membrane in several ways. For instance, proteolytic activation by FVIIa is of importance for activating the G-protein-coupled protease-activated receptors (PAR) 1 and 2 [13], whereas a more direct physical interaction with TF/FVIIa seems significant for activation of certain β1-integrin (ITGβ1) complexes [14, 15]. TF also has a short intracellular domain containing three serines as potential phosphorylation sites [16].
One of the biological consequences of TF signaling is suppression of apoptosis. A protective role of the TF/FVIIa complex was first described in serum starved baby hamster kidney cells and Chinese hamster ovary (CHO) cells and later also in Adr-MCF7 and MDA-MB-231 breast cancer cells [17]. The reduction in caspase-3 activation was dependent on the proteolytic activity of FVIIa and the PI3-kinase/AKT signaling pathway, but independent of FXa and thrombin. Serum depletion from the MDA-MB-231 cells also activated caspase-8, the initiator caspase in the extrinsic pathway [18]. Similar to caspase-3, caspase-8 activation was sensitive to TF/FVIIa-dependent signaling. TNF-related apoptosis-inducing ligand (TRAIL) is expressed in immune cells of healthy individuals and induces apoptosis in a variety of cell types through binding to the DR4/DR5 death receptors [19–21]. A rapid up-regulation of both caspase-8 and -3 was recorded after TRAIL-receptor activation in both MDA-MB-231 breast and PC3 prostate cancer cells which was reduced after treatment with FVIIa [18].

The insulin-like growth factor 1 receptor (IGF-1R) is a transmembrane receptor tyrosine kinase (RTK) involved in regulating apoptosis, proliferation, differentiation, and motility. Altered IGF-1R signaling contributes to several pathological conditions including cancer [22]. Activation of the IGF-1R, either directly by its ligand IGF-1 or indirectly by other proteins through so called transactivation [23], results in phosphorylation of its intracellular β-subunits. We have previously recorded a dose-dependent transactivation of the IGF-1R in several principally different cell types: human breast cancer cells and human aortic smooth muscle cells with constitutive expressions of TF, human monocytes primed to express TF, and porcine aortic endothelial cells transfected with human TF, this after treatment with fully functional FVIIa but not after treatment with an active-site inhibited FVIIa [16, 24]. Inhibition or removal of IGF-1R blocked the FVIIa-mediated phosphorylation of AKT as well as the protection against TRAIL-induced apoptosis in cancer cells [24]. Treatment with FVIIa furthermore induced a translocation of a SUMOylated IGF-1R to the nuclei where it acted as a transcription enhancer and induced mRNA production. By using siRNA, receptor blocking antibodies and peptide agonists, PAR1 and PAR2 was ruled out as transducers of the survival signals directly downstream of TF/FVIIa [18, 24]. In a similar approach, we used porcine cells transfected with human TF with a modified cytoplasmic domain to show that TF did not have to be phosphorylated to transactivate IGF-1R [24]. In conclusion, it is today not known how the anti-apoptotic signal is transduced between TF/FVIIa and IGF-1R and the elucidation of this mechanism is therefore the subject of this study.

Both TF and IGF-1R have been associated with domains termed caveolae [25–27]. These are stable invaginations of the cell surface plasma membrane with a high content of proteins and act as signaling nodes. Caveolin-1 (Cav1) is the principal protein of the caveolae and has the ability to bind and regulate the activity of signaling proteins via an area between residues 82–101 termed the caveolin scaffolding domain [28, 29]. A conserved caveolin scaffolding domain binding motif has been identified in several RTKs including the IGF-1R [30].

We now demonstrate that TF/FVIIa-dependent ITGβ1 activation results in Cave1 Tyr14 phosphorylation by Src-family kinases. By interfering with ITGβ1, Src, or Cav1 activation we eliminated both the ability of TF/FVIIa to rescue cancer cells from TRAIL-induced apoptosis and the ability to induce IGF-1R-dependent protein production.

Materials and methods

Reagents

Cav1 scaffolding domain peptide and control peptide [31] were purchased from Merck Millipore USA. The Src-family inhibitors SU6656 and PP2, PAR1-activating peptide (SFLLRN), PAR2-activating peptide (SLIGKV), geranyl-geranyl pyrophosphate (GGPP), and simvastatin were bought from Sigma-Aldrich Sweden AB. Simvastatin was activated prior to the experiments by alkaline hydrolysis of the lactone ring according to the manufacturer’s protocol. Recombinant human FVIIa was a kind gift from Professor LC Petersen, NovoNordisk A/S, Denmark. The following antibodies were purchased: rabbit IGF-1Rβ, Cav1 rabbit, pSrc family Tyr416, Caspase-3, Cyclin-D1, β-actin, and pAbl Tyr245 from Cell Signaling Technology, USA; phosphotyrosine rabbit, HDAC-2 from Abcam, UK; Cav1 mouse from Santa Cruz Biotechnology, USA; Abl, activated β1 integrin (HUTS-4), and phosphotyrosine 4G10 Platinum from Merck Millipore USA. The Src-family inhibitors SU6656 and PP2, PAR1-activating peptide (SFLLRN), PAR2-activating peptide (SLIGKV), geranyl-geranyl pyrophosphate (GGPP), and simvastatin were bought from Sigma-Aldrich Sweden AB. Simvastatin was activated prior to the experiments by alkaline hydrolysis of the lactone ring according to the manufacturer’s protocol. Recombinant human FVIIa was a kind gift from Professor LC Petersen, NovoNordisk A/S, Denmark. The following antibodies were purchased: rabbit IGF-1Rβ, Cav1 rabbit, pSrc family Tyr416, Caspase-3, Cyclin-D1, β-actin, and pAbl Tyr245 from Cell Signaling Technology, USA; phosphotyrosine rabbit, HDAC-2 from Abcam, UK; Cav1 mouse from Santa Cruz Biotechnology, USA; Abl, activated β1 integrin (HUTS-4), and phosphotyrosine 4G10 Platinum from Merck Millipore USA.

Cell lines

PC3 and DU145 prostate cancer cells and MDA-MB-231 breast cancer cells were purchased from American Type Culture Collection (USA) and were grown in RPMI1640 (Gibco/Invitrogen) supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 100 U/ml penicillin, and 100 µg/ml streptomycin in a humidified chamber at 37 °C, 5% CO2. All cell lines have previously been verified for their expression of TF [32].
RNA interference

Silencer® Select Validated siRNA toward Cav1, ITGβ1, TF and scramble RNA (10 nM, Ambion/Life Technologies, USA) were transfected into the PC3 cells using Lipofectamine® RNAiMAX Transfection Reagent (Life Technologies). The reduction in expression levels (S-fig S1) and the functional experiments were assessed 72 h post transfection.

Real-time quantitative PCR

Real-time quantitative PCR analyses of Cav1, GAPDH, ITGβ1, and β2 microglobulin (Assay-on-demand, Applied Biosystems, USA) were performed on cDNA originating from oligoDT (Invitrogen) converted total RNA extracted using Trizol® (Invitrogen). The samples were run and analyzed on an AbiPrism 7500 (Applied Biosystems).

In situ proximity ligase assay

The proximity of antibodies targeting antigens of interest was monitored with the Duolink In situ assay (Sigma-Aldrich). Blocking solution, antibody dilution and washing buffers were supplied by the manufacturer. Briefly, PC3 cells were grown on chamber slides and then treated as indicated in the figures. The cells were then fixed in 2% paraformaldehyde, permeabilized in 0.2% TX-100 and blocked. Primary antibodies in optimized concentrations were added as indicated in the figures prior to the incubation with secondary oligonucleotide-conjugated PLA probes. If in close proximity (<40 nm) and in the presence of a ligase, the PLA probes hybridized. Amplification solution, consisting of nucleotides and fluorescently labeled oligonucleotides, was added together with Polymerase to generate a rolling-circle amplification (RCA), resulting in an RCA product to which the fluorescently labeled oligonucleotides could hybridize. The localized amplification reaction increases the sensitivity by a 1000-fold and gives a lower limit of detection in the femtomolar range [33]. This gives a considerable increase in antibody/protein co-localization resolution also when compared to traditional double-label indirect immune fluorescence microscopy [34]. The nuclei and cytoskeleton (Fig. 4a only) were counterstained with DAPI and phalloidin respectively, and Z-stack images were captured using an AxioImager M2 fluorescence microscope at 20X magnification (Carl Zeiss AB, Sweden). The images were then analyzed using Blob Finder software (https://www.cb.uu.se/~amin/BlobFinder/). The images in the figures are magnifications from maximum-intensity projections over the entire image volume.

Preparation of membrane and nuclear protein fractions

PC3 cells (0.75 × 10⁶ / ml) were either left untreated or were preincubated for 3 h with 5 nM with a Cav1 scaffolding domain membrane permeable peptide, and then stimulated with 10 nM or 100 nM FVIIa for 30 min. The cells were then lysed and the membrane, nuclear soluble and chromatin-bound cellular fractions were separated using a Subcellular Fractionation Kit according to the manufacturer’s instructions (Thermo Scientific/Pierce Biotech, USA). The fractions were analyzed for the expression of IGF-1R and HDAC-2 by western blot (WB).

Western blot

After being treated as indicated in the figures, the PC3 cells were lysed in 2% SDS sample buffer supplemented with 5% beta-mercaptoethanol. The proteins were then separated by SDS-PAGE and transferred onto Immobilon-FL PVDF membranes (Merck Millipore). The membranes were blocked in Odyssey blocking buffer (Licor) and left overnight at 4 °C in blocking buffer containing the primary antibodies. The membranes were then washed in TBS 0.01% Tween-20 and incubated with secondary antibodies conjugated to IR-Dyes 680 and 800 for 60 min (Licor). The membranes were finally scanned and the bound proteins were visualized with the Odyssey Infrared Imaging System (Licor) and quantified using Odyssey V3.0 software.

Flow cytometry

The PC3 cells were incubated with or without 10 nM FVIIa for 1, 5, 15, and 20 min and permeabilized with 0.2% Triton-X-100 in PBS for 15 min at room temperature. The cells were then washed in PBS with 0.5% FBS and incubated with FITC-labeled antibodies against the active conformation of ITGβ1 or IgG (isotype control). The protein expression was then analyzed in a Cytomics FC500 Flow Cytometer and the MFI values calculated using Kaluza Analysis Software (both Beckman Coulter Inc., USA).

Statistics

Statistical values were calculated using Graph Pad Prism 8.0 (GraphPad software, Inc., USA) and the bars indicate mean + SEM. Unpaired Students t-test was used to evaluate the significance between two groups. For comparison of three or more groups, one-way ANOVA with Dunnett’s
post-hoc calculation was applied. P-values ≤ 0.05 were considered statistically significant.

**Results**

**The transactivation of IGF-1R by TF/FVIIa is conveyed by β1 integrins**

PC3 prostate cancer cells were treated with FVIIa for 30 min, and the proximity between TF and activated ITGβ1 on the cell surface was investigated by PLA in situ. Only a few signals were found in the untreated control cells, whereas the number of signals was increased about threefold by FVIIa treatment (Fig. 1a). The PC3 cells were treated with FVIIa for shorter time periods, and the ITGβ1 activation was monitored by flow cytometry. A significant increase was detected after 5, 15, and 20 min (Fig. 1b). Next, the transactivation of IGF-1R by TF/FVIIa was evaluated by PLA in situ in PC3 cells (serving as control), and in PC3 cells treated with scramble and ITGβ1 siRNA (Fig. 1c). In both the control cells and the scramble-treated cells a twofold increase of IGF-1R phosphorylation was detected. No activation of the IGF-1R could be recorded in the ITGβ1 siRNA treated cells. These experiments indicate that FVIIa treatment increases the interplay between ITGβ1 and TF and that the subsequent activation of ITGβ1 is important for the TF/FVIIa-dependent transactivation of IGF-1R.

**The FVIIa-induced phosphorylation of the IGF-1R is regulated by the caveolin-1 scaffolding domain.**

The IGF-1R and Cav1 proteins were found to be in close proximity in situ in resting cells and the treatment with FVIIa did not alter the distance between the proteins in any way reflected by the PLA assay (Fig. 2a). Since Cav1 is the defining protein of caveolae, it is plausible to assume that the IGF-1R is present within caveolae on the PC3 cellular surface.

Cav1 expression was then decreased in the PC3 cells by siRNA which led to an increased phosphorylation of IGF-1R (Fig. 2b). FVIIa treatment induced IGF-1R phosphorylation in the scramble group but did not further contribute to IGF-1R activation in cells with reduced levels of Cav1 (Fig. 2b).

To further examine the role of Cav1, PC3 cells were pretreated for 3 h with a commercially available, cell membrane penetrating Cav1 scaffolding domain peptid (mimicking Cav1 overexpression) or with a scrambled Cav1 scaffolding domain peptid and then incubated with FVIIa for 30 min (Fig. 2c). The IGF-1R phosphorylation was increased in FVIIa-treated cells and in the cells treated with FVIIa and scrambled peptide, but the TF/FVIIa-complex did not induce phosphorylation of IGF-1R in the Cav1 scaffolding domain peptid group. This suggests that Cav1 has a dampening effect on IGF-1R activation.

**Simvastatin treatment inhibits caveolin-1 transcription and increases the phosphorylation of the IGF-1R**

Data describing a reduction of Cav1 mRNA levels in canine cells after treatment with the cholesterol synthesis inhibitor simvastatin have previously been published [35]. PC3 cells were therefore incubated with or without different concentrations of simvastatin or the cholesterol transport inhibitor U18666A in normal culture media for different time-points. The distribution of cell surface cholesterol (S-Fig. 2) as well as TF and IGF-1R mRNA levels were monitored (S-Fig. 3). Based on these data, we decided to use 500 nM simvastatin, 1.25 µM U18666A and the time-point 72 h for further experiments. At these settings, the cell surface levels of cholesterol were reduced by both treatments but the transcription of TF and IGF-1R were unaffected.

The Cav1 expression was then measured after incubation with FVIIa, simvastatin and U18666A. Treatment with simvastatin, but not U18666A, reduced Cav1 mRNA and protein levels by approximately 30% (Fig. 3a and b) indicating that the cell surface level of cholesterol was not involved in the regulation of Cav1. Co-incubation of the PC3 cells with 500 nM simvastatin and the cholesterol synthesis pathway intermediate GGPP blunted the effects of simvastatin on Cav1 mRNA transcription (Fig. 3a). Simvastatin thus regulates the transcription of Cav1 in a seemingly cholesterol independent manner.

Addition of FVIIa to untreated cells, or to cells treated with U18666A increased the phosphorylation of the IGF-1R, whereas the IGF-1R was activated regardless of the presence of FVIIa in the simvastatin treated cells (Fig. 3c). U18666A had no effect on its own on the IGF-1R phosphorylation. Similar results were thereby recorded after reduction of Cav1 by simvastatin as after treatment with Cav1 siRNA.
Fig. 1 The transactivation of IGF-1R by TF/FVIIa is conveyed by β1-integrins. a PC3 cells were treated with 100 nM FVIIa for 30 min, and the co-localization of TF and activated ITGβ1 was determined by PLA as described in Methods. A fluorescence signal from each detected pair is seen as a distinct individual dot (red) whereas the nuclei are shown in blue. Images are magnifications from maximum intensity projections over the entire image volume, captured with a 20X objective on an AxioImager M2 fluorescence microscope. The Z-stacks were analyzed with Blob Finder software. N = 4. b PC3 cells were treated with 10 nM FVIIa for 1, 5, 15, and 20 min and the Mean Fluorescence Intensity (MFI) of activated ITGβ1 was monitored by flow cytometry as described in Methods. N = 5. c PC3 cells were incubated with scramble or ITGβ1 siRNA for 72 h and then treated with 100 nM FVIIa for 30 min. The phosphorylation of the IGF-1R was analyzed by PLA and antibodies toward IGF-1Rβ and phosphotyrosine (pY). N = 3–11. * = p ≤ 0.05 ** = p ≤ 0.01 *** = p ≤ 0.001
TF/FVIIa induces a phosphorylation of tyrosine 14 on caveolin-1 in a β1 integrin-dependent manner

Since FVIIa did not alter the proximity between Cav1 and IGF-1R (Fig. 2a) or the protein levels of Cav1 (Fig. 3b) we investigated if the TF/FVIIa-complex could induce Cav1 phosphorylation. The PC3 cells were treated with FVIIa and by utilizing PLA we recorded an increased pTyr of Cav1 after 10 and 30 min (Fig. 4a-b). We verified the PLA data by using a second Cav1—pTyr antibody pair with similar results (Fig. 4b). An increase in Cav1 phosphorylation was also recorded by WB, using an antibody directed toward phosphorylated Cav1α, after 30 min of incubation with FVIIa (Fig. 4c). Treatment with recombinant IGF1 or the PAR1 agonist SFLLRN or the PAR2 agonist SLIGKV did not induce a Cav1 Tyr14 phosphorylation in our experimental setup (Fig. 4c, for functional testing of the PAR1 and PAR2 agonists please see S-Fig. 4). There was furthermore no phosphorylation of Cav1 by FVIIa after siRNA mediated down regulation of TF (Fig. 4d). This means that FVIIa needs to bind to TF to initiate the Cav1 phosphorylation.

To test if the TF/FVIIa-induced Cav1 phosphorylation was dependent on ITGβ1, PC3 cells were treated with ITGβ1 siRNA prior to the addition of FVIIa. In control cells and scramble siRNA-treated cells a Cav1 phosphorylation was recorded, whereas in the ITGβ1 knocked cells no Cav1 phosphorylation was detected (Fig. 4e). The combined data from the PLA and WB experiments thereby strongly indicate that FVIIa, in contrast to IGF1 and PAR1/2 agonists, phosphorylates the Cav1α isoform on tyrosine 14 in a TF and ITGβ1-dependent manner.

Fig. 2 The FVIIa-induced phosphorylation of the IGF-1R is regulated by the caveolin-1 scaffolding domain a PC3 cells were treated with 100 nM FVIIa for 30 min, and the proximity of IGF-1Rβ and Cav1 was determined by PLA as described in Methods. A fluorescence signal from each detected pair is seen as a distinct individual dot (red) whereas the nuclei are shown in blue. Images are magnifications from maximum intensity projections over the entire image volume, captured with a 20X objective on an AxioImager M2 fluorescence microscope. The Z-stacks were analyzed with Blob Finder software N = 3. b PC3 cells were incubated with siRNA targeting Cav1 or a scrambled sequence for 72 h and then treated with 100 nM FVIIa for 30 min. The phosphorylation of the IGF-1R was assessed using PLA as described in Methods. Red = PLA signals, blue = nuclei. N = 3. c PC3 cells were preincubated for 3 h with 5 nM of either a Cav1 scaffolding domain peptide or a scrambled peptide of equal length, and then treated with 100 nM FVIIa for 30 min. The phosphorylation of the IGF-1R was recorded using PLA and quantified as described in Methods. N = 3. * = p ≤ 0.05 *** = p ≤ 0.001

Fig. 3 Simvastatin treatment increases the phosphorylation of the IGF-1R by down-regulation of caveolin-1 a PC3 cells were treated for 72 h with 500 nM simvastatin, 500 nM simvastatin + 5 µM GGPP, or with 1.25 µM U18666A. Cav 1 mRNA levels were then assessed using qRT-PCR as described in Methods and normalized toward GAPDH. N = 4–5. b PC3 cells were treated with 500 nM simvastatin or 1.25 µM U18666A for 72 h and then incubated with 100 nM FVIIa for 30 min. Cav1 protein levels were then assessed using WB as described in Methods and normalized toward GAPDH. N = 5. c PC3 cells were treated with 500 nM simvastatin or 1.25 µM U18666A for 72 h and then incubated with 100 nM FVIIa for 30 min. The phosphorylation of the IGF-1R was then assessed using PLA as described in Methods. Red = PLA signals, blue = nuclei. N = 6–8. * = p ≤ 0.05 ** = p ≤ 0.01 *** = p ≤ 0.001. # = p ≤ 0.05 vs U18666A treated cells
The FVIIa-induced phosphorylations of caveolin-1 and IGF-1R are Src-family-dependent

Cav1 Tyr14 is phosphorylated by kinases belonging to the Abl and Src families [36, 37]. We found no differences in Abl phosphorylation between untreated and FVIIa-treated PC3 cells when using an Abl Tyr245-specific antibody in WB (Fig. 5a). A higher concentration of FVIIa, different time points, and the use of the more sensitive PLA method produced similar results (Fig. 5b). In contrast, FVIIa induced a phosphorylation of Src family members on tyrosine 416 (Fig. 5c).
The PC3 cells were treated for one hour with two different concentrations of the Src inhibitors SU6656 or PP2 followed by incubation with FVIIa. Src inhibition reduced the FVIIa-induced phosphorylation of Cav1 to levels comparable to untreated cells (Fig. 5d). Similar results were also found in MDA-MB-231 breast cancer cells and DU145 prostate cancer cells (Fig. 8a and S-Fig. 5, respectively). The impact of Src inhibition on IGF-1R activation in FVIIa-treated PC3 cells was also determined in situ. The number of detectable pTyr IGFR-1 PLA signals was reduced in the Src-inhibited PC3 cells (Fig. 5e). From these results we conclude that both the phosphorylation of Cav1 and the phosphorylation of IGF-1R by TF/FVIIa are sensitive to inhibition of Src-family kinases.

---

**Fig. 4** TF/FVIIa induces a phosphorylation of tyrosine 14 on caveolin-1 in a β integrin-dependent manner a PC3 cells were treated with 100 nM FVIIa for 10 min and the proximity of antibodies binding to Cav1 and phosphotyrosine (pY) was assessed using PLA as described in Methods. Red = PLA signals, blue = nuclei, green = cytoskeleton. Images are magnifications from maximum intensity projections over the entire image volume, captured with a 20X objective on an Axiosimager M2 fluorescence microscope. The Z-stacks were analyzed with Blob Finder software. b The images captured in Fig. 4A as well as PLA images from PC3 cells treated with 100 nM FVIIa for 30 min were analyzed as described in Methods. Different combinations of mouse (m) and rabbit (r) antibodies binding to Cav1 and phosphotyrosine were used as indicated. N = 3–5. c PC3 cells were treated with 10 nM FVIIa, 100 ng/ml IGF1, 50 µl PAR1 agonist SFLLRN, or 50 µM PAR2 agonist SLIGKV for 30 min, and the pCav1 Tyr14 and Cav1 levels were analyzed by WB as described in Methods. The levels of pCav1 Tyr14 were normalized toward Cav1. N = 4–8. d–e PC3 cells were incubated with scramble, TF or ITGβ1 siRNA for 72 h and then treated with 10 nM FVIIa for 30 min. The pTyr14 phosphorylation of Cav1 was analyzed by WB as described in Methods. N = 4–6.

* = p ≤ 0.05 ** = p ≤ 0.01 *** = p ≤ 0.001

**Fig. 5** The FVIIa-induced phosphorylations of caveolin-1 and IGF-1R are Src-family dependent a PC3 cells were treated with 10 nM FVIIa for 30 min. Levels of pABL (Y245) and ABL were analyzed by WB as described in Methods and expressed as a ratio of pABL(Y245) / ABL. N = 4. b PC3 cells were treated with 100 nM FVIIa for 10, 20 and 30 min. The phosphorylation of the ABL was recorded using PLA and quantified as described in Methods. N = 2. c PC3 cells were treated with 10 nM FVIIa for 30 min. Protein levels of pSrc (Y416) and GAPDH were analyzed by WB as described in Methods and expressed as a ratio of pSrc (Y416) / GAPDH. N = 6. d PC3 cells were pretreated with the Src-family inhibitors SU6656 (SU) or PP2 for 1 h as indicated. The cells were then stimulated with 10 nM FVIIa for 30 min and the levels of pTyr14 on Cav1 assessed with WB as described in Methods. The immunoblots were quantified and pCav1 Tyr14 normalized toward Cav1. N = 4–8. e PC3 cells were pretreated with Src-family inhibitors for 1 h as indicated and then incubated with 100 nM FVIIa for 30 min. The phosphorylation of the IGF-1R was then assessed using PLA as described in Methods. Red = PLA signals, blue = nuclei. N = 5–7. * = p ≤ 0.05 ** = p ≤ 0.01 *** = p ≤ 0.001
The nuclear translocation of IGF-1R is dependent on β1 integrin and caveolin-1

PC3 cells were pre-treated with the Cav1 scaffolding domain peptide for 3 h (in the same concentration that prevented IGF-1R phosphorylation, Fig. 2c) before addition of FVIIa. The nuclear IGF-1R translocation was then assessed by WB on fractionated cell lysates. Nuclear IGF-1R was increased in both the soluble nuclear and chromatin-bound cell fractions post FVIIa treatment (Fig. 6a). The presence of the Cav1 scaffolding domain peptide completely blocked the FVIIa-dependent nuclear IGF-1R enrichment. Similar data was found by PLA in situ (Fig. 6b).

We have previously shown how TF/FVIIa signaling induce transcription of the cyclin-D1 gene in breast cancer cells by using real-time PCR [24]. Figure 6c shows that the induction of PC3 cells by FVIIa increased the cyclin-D1 protein levels in control cells and in scramble siRNA-treated cells, whereas ITGβ1 siRNA treatment blocked this up-regulation.

The anti-apoptotic signaling by TF/FVIIa/IGF-1R is dependent on β1 integrin and caveolin-1

Apoptosis was induced in the PC3 cells by treatment with the death receptor agonist TRAIL for 3 h. The cells were also treated with the Cav1 scaffolding-domain peptide and/or FVIIa and the activation of caspase-3 was monitored by WB (Fig. 7a). The activation of caspase-3 by TRAIL was reduced in the presence of FVIIa but the protective effect of FVIIa was canceled by the Cav1 peptide. The Cav1 peptide did not activate caspase-3 on its own.

The PC3 cells were then treated with siRNA towards ITGβ1 and again challenged by TRAIL (Fig. 7b). FVIIa retained its protective effect in the control cells and the cells transfected with scramble siRNA, whereas the knockdown of ITGβ1 resulted in a loss of anti-apoptotic signaling by the TF/FVIIa complex.

Finally, we successfully verified the FVIIa-dependent Cav1 phosphorylation (Fig. 8a) and the importance of Cav1 (Fig. 8b) and ITGβ1 (Fig. 8c) on the anti-apoptotic signaling downstream of TF in MDA-MB-231 breast cancer cells.

![Fig. 6](image)

**Fig. 6** The nuclear translocation of IGF-1R is dependent on β1 integrin and caveolin-1. a PC3 cells were left untreated or were pre-incubated for 3 h with 5 nM of a Cav1 scaffolding domain peptide and then stimulated with 10 nM FVIIa for 30 min. Membrane, nuclear soluble and chromatin-bound protein extracts were analyzed for IGF-1Rβ and HDAC-2 by WB as described in Methods. The nuclear soluble and chromatin-bound fractions were quantified and normalized toward HDAC-2. N=4–5. b PC3 cells were left untreated or were pre-incubated for 3 h with 5 nM of a Cav1 scaffolding domain peptide and then stimulated with 100 nM FVIIa for 30 min. Nuclear IGF-1Rβ was detected using PLA and quantified as described in Methods. N = 3. c PC3 cells were incubated with scramble or ITGβ1 siRNA for 72 h and then treated with 10 nM FVIIa for 30 min. The protein levels of cyclin D1 and β-actin were analyzed by WB as described in Methods and expressed as a ratio of cyclin-D1 / β-actin. N=5. *p ≤ 0.05 **p ≤ 0.01 ***p ≤ 0.001

© Springer
Discussion

The aim of this study was to determine the pathway between TF and the RTK IGF-1R after FVIIa treatment, with the subsequent anti-apoptotic effect and protein production as biological read-outs. We propose a model that starts with TF/FVIIa-dependent activation of ITGβ1, which leads to Src-dependent phosphorylation of Cav1 and finally IGF-1R signaling and downstream effects (Fig. 9).

Signaling by the TF/FVIIa complex is known to induce transactivation of the EGFR and PDGFRβ. The signaling pathways between TF and these two RTKs have been described as Src-family dependent [38, 39] and similar data can now be shown for IGF-1R, with the addition that phosphorylation of Src was found to be conveyed by ITGβ1. Integrins are activated by conformational changes of the extracellular domains to induce bi-directional signaling of importance for e.g. cell survival [40, 41]. An interplay between TF and β1, α3, and α6 integrin subunits has been reported by others [14]. Consistent with our previously published data on the transactivation of IGF-1R by TF/FVIIa [18, 24] is the formation of the TF/FVIIa/ITGβ1 complex dependent on FVIIa but not on a phosphorylated cytoplasmic TF domain or the activation of PAR2 [15]. In our experimental setup, extracellular matrix (ECM) from serum in the cell media or produced by the cells might have contributed to the transactivation of IGF-1R by interacting with ITGβ1. Both long and short effects in our experiments were, however, seen after the addition of FVIIa to the cells. This indicates that ITGβ1 expression per se is insufficient. FVIIa treatment increases the amount of ITGβ1 present in its active conformation, which indicates that regardless binding of ITGβ1 to ECM or not, there is a dependency on the formation of the TF/FVIIa complex for this activation.

Interestingly, an integrin-binding motif in the FVIIa protease domain required for the association of TF/FVIIa with ITGβ1 was recently described [15]. This means that TF, in this case, most likely functions as a co-factor/scaffold to FVIIa which in turn associates with ITGβ1 to induce the conformational changes required for ITGβ1 activation. In the light of this information should the PLA data presented in Fig. 1a therefore be interpreted as a complex formation between TF/FVIIa/activated ITGβ1 and not only between TF and activated ITGβ1.

Two antibodies directed at different domains of TF affect the interaction of the binary TF-complex and ITGβ1 in opposite ways. The antibody TF-5G9 reportedly increases the association of TF with integrins on a similar level as FVIIa, whereas TF-10H10 specifically disrupts this association [14]. We have previously published data that shows a negative impact of TF-10H10 on the IGF-1R pathway...
dependent anti-apoptotic effects of FVIIa [18]. This fits with the assumption that the protective effect of TF/FVIIa is ITGβ1-dependent.

Many proteins regulated by caveolin, including IGF-1R, share a common amino acid sequence motif that binds to the Cav1 scaffolding domain [30]. This interaction inhibits the autophosphorylations of EGFR in A431 cells and CHO cells and of PDGFα and -β in NIH3T3 fibroblasts [42, 43]. It also stabilizes TGFβR1, and TrkA in inactive conformations until activation by ligands [44, 45]. Our data suggest that the scaffolding domain seems to have an impeding effect also on IGF-1R activation. The Cav1 scaffolding domain

![Fig. 8 Caveolin-1 phosphorylation and anti-apoptotic signaling in MDA-MB-231 cells after FVIIa treatment. a MDA-MB-231 cells were pretreated with the Src-family inhibitors SU6656 (SU) or PP2 for 1 h as indicated. The cells were then stimulated with 10 nM FVIIa for 30 min and the levels of pTyr14 on Cav1 assessed with WB as described in Methods. The immunoblots were quantified and pCav1 Tyr14 normalized toward Cav1. N = 6–7. b MDA-MB-231 cells were treated with 100 ng/ml TRAIL, 5 nM Cav1 scaffolding domain peptide, and 10 nM FVIIa for 3 h as indicated. Apoptosis was monitored by measuring the activation of caspase-3 with WB as described in Methods. The caspase-3 bands were quantified and normalized toward β-actin. N = 5–6. c PC3 cells were incubated with scramble or ITGβ1 siRNA for 72 h and then treated with 100 ng/ml TRAIL and 10 nM FVIIa for 3 h as indicated. Apoptosis was monitored by measuring the activation of caspase-3 with WB as described in Methods. The caspase-3 bands were quantified and normalized toward β-actin. N = 4. * = p ≤ 0.05 ** = p ≤ 0.01 *** = p ≤ 0.001]
peptide used in this study have previously been shown to block eNOS activity and cellular NO release in vitro and to reduce inflammation and tumorigenesis in vivo, but data on its role in IGF-1R signaling is lacking [31, 46].

There are contrasting results presented in the literature concerning the mutual relations of IGF1 signaling and Cav1. Knockdown of Cav1 reduces e.g. IGF1 signaling in H9C2 rat cardiomyoblasts [47] whereas Cav1 overexpression significantly increases IGF1-induced internalization of IGF-1R in human hepatocellular carcinoma cells [48]. Cav1 is also Tyr14 phosphorylated in response to IGF1 treatment in mouse fibroblasts transfected with human IGF-1R [49]. Some of these discrepancies might be explained by the biological differences between a direct agonist activation of a receptor and a receptor transactivation. The transactivation of IGF-1R and PDGFRβ by TF/FVIIa leads to a delayed, partial activation of the receptor [24, 39]. Similarly, integrin-mediated activation of Src in urinary bladder carcinoma cells leads to a phosphorylation pattern in the kinase domain of EGFR that is different from that induced by the binding of EGF to EGFR [50]. The kinetics of Cav1 phosphorylation seems also to depend on the received stimuli. The activation after IGF1 treatment is recordable between 5 and 15 min in mouse fibroblasts [49] but not after 30 min. In contrast, it is still present at 30 min after addition of FVIIa in our model system. Considering these differences, it is difficult to discuss the conflicting data on a detailed level except to draw the conclusions that the outcome of protein interactions with Cav1 seems, to some extent, to be dependent on the cell type, the proteins, and type of stimuli. Since we were able to show a TF dependent phosphorylation of Cav1 by FVIIa (Fig. 4d) in three different cell lines (Fig. 5d, Fig. 8a, S-Fig. 5) this connection was, however, not exclusive to PC3 cells.

In the present study we focused on finding a mechanism to explain the transactivation of IGF-1R by TF/FVIIa and the previously known biological mechanisms of increased cell survival and IGF-1R nuclear translocation. The wide-spanned effects of IGF-1R and others RTKs entail a tight regulation of transcription and translation and also of their ligand availability. Since RTK activity drives many types of diseases, much effort has been put into the development and testing of pharmacological inhibitors towards the different receptors. The spatial distribution of receptors and the bypassing of ligands could, however, substantially affect the success of such targeted therapies, which is exemplified by the apparent failures of IGF-1R inhibitors in cancer patients [22, 51]. RTK transactivation and the aberrant spatial regulation of RTKs are therefore regarded as a promising field in the search for new therapies [52].

The first report on TF-dependent anti-apoptotic signaling described a protective effect of FVIIa in serum starved baby hamster kidney cells [17]. In a later study we detected activated caspase-8 24 h after serum withdrawal in breast cancer cells and noticed that treatment with FVIIa reduced the formation of the death inducing signaling complex (DISC) responsible for caspase-8 activation [18]. These data provided a new angle on TF/FVIIa-mediated cell survival
aiming at the extrinsic pathway. To get a more refined cellular model we have since then treated cancer cells with TRAIL which triggers apoptosis by binding to DR4/DR5 receptors. This binding leads to intracellular assembly of the DISC and cleavage of caspase-8 which then directly activates caspase-3 i.e. the apoptosis marker used in this study. In vivo, TRAIL is expressed in many tissues and on the surface of some immune cells [20, 21] and is present both as a cell bound protein and in a soluble form. For instance, TRAIL-expressing T cells are described to induce apoptosis in vascular smooth muscle cells (VSMC) after cell–cell interactions whereas IFNα-treated monocytes are primed to release the soluble form of TRAIL [21, 53]. Recombinant TRAIL has gained interest as a potential cancer therapeutic drug and the power of TRAIL-based therapies stems from TRAILs explicit cancer cell-selectivity over normal cells. Recent reports do, however, report that tumor cells can acquire TRAIL resistance by several mechanisms [19]. VSMC and many cancer cells express TF and the presence of FVIIa within the plaque or in the vicinity of the tumor may therefore result in both a decreased risk for plaque rupture and an increased survival of the cancer cells. The TF/FVIIa-dependent anti-apoptotic effects may thereby have a dual role in the body. This is of importance to keep in mind since the TF-10H10 antibody and the Cav1 scaffolding domain peptide both target the TF/FVIIa/IGF-1R pathway and might thus serve as treatment tools in different diseases. As a cautionary note, recent publications assign TF-dependency to other pathways whereas IFNα-treated monocytes are primed to release procoagulant microvesicles from human monocytes and differentially increases tissue factor in human monocyte subsets. Thromb Haemost 117:1379–1390

References

1. Grover SP, Mackman N (2018) Tissue Factor: An Essential Mediator of Hemostasis and Trigger of Thrombosis. Arterioscler Thromb Vasc Biol 38:709–725
2. Tripodi A, Branchi A, Chantarangkul V et al (2011) Hypercoagulability in patients with type 2 diabetes mellitus detected by a thrombin generation assay. J Thromb Thrombolysis 31:165–172
3. Hisada Y, Mackman N (2017) Cancer-associated pathways and biomarkers of venous thrombosis. Blood 130:1499–1506
4. Stojkovic S, Thulín A, Hell L et al (2017) IL-33 stimulates the release of procoagulant microvesicles from human monocytes and differentially increases tissue factor in human monocyte subsets. Thromb Haemost 117:1379–1390
5. Mueller BM, Reisfeld RA, Edgington TS, Raf W (1992) Expression of tissue factor by melanoma cells promotes efficient hemanogogenous metastasis. ProcNatlAcadSciUSA 89:11832–11836
6. Siegbahn A, Johnell M, Rorsman C, Ezban M, Heldin CH, Ronnstrand L (2000) Binding of factor VIIa to tissue factor on human fibroblasts leads to activation of phospholipase C and enhanced PDGF-BB-stimulated chemotaxis. Blood 96:3452–3458
7. Rottingen JA, Enden T, Camerer E, Iversen JG, Prydz H (1995) Binding of human factor VIIa to tissue factor induces cytosolic Ca2+ signals in J82 cells, transfected COS-1 cells, Madin-Darby canine kidney cells and in human endothelial cells induced to synthesize tissue factor. J Biol Chem 270:4650–4660
8. Šato Y, Asada Y, Marutskka K, Hatakeyama K, Sumiyoshi A (1996) Tissue factor induces migration of cultured aortic smooth muscle cells. Thromb Haemost 75:389–392
9. Cirillo P, Cali G, Golino P et al (2004) Tissue factor binding of activated factor VII triggers smooth muscle cell proliferation via extracellular signal-regulated kinase activation. Circulation 109:2911–2916
10. Callander NS, Varki N, Rao LV (1992) Immunohistochi- cal identification of tissue factor in solid tumors. Cancer 70:1194–1201
11. Shigemori C, Wada H, Matsumoto K, Shiku H, Nakamura S, Suzuki H (1998) Tissue factor expression and metastatic potential of colorectal cancer. ThrombHaemost 80:894–898
12. Ueno T, Toi M, Koike M, Nakamura S, Tominaga T (2000) Tissue factor expression in breast cancer tissues: its correlation with prognosis and plasma concentration. Br Cancer 83:164–170
13. Zelaya H, Rothmeier AS, Raf W (2018) Tissue factor at the crossroad of coagulation and cell signaling. Journal of thrombosis and haemostasis : JTH 16:1941–1952
14. Versteeg HH, Schaffner F, Kerver M et al (2008) Inhibition of tissue factor signaling suppresses tumor growth. Blood 111:190–199
15. Rothmeier AS, Liu E, Chakrabarty S et al (2018) Identification of the integrin-binding site on coagulation factor VIIa required for proangiogenic PAR2 signaling. Blood 131:674–685
16. Aberg M, Eriksson O, Siegbahn A (2015) Tissue Factor Noncoagulant Signaling: Mechanisms and Implications for Cell Migration and Apoptosis. Semin Thromb Hemost 41:691–699
17. Sorensen BB, Raa LV, Tornehave D, Gammeltoft S, Petersen LC (2003) Antiapoptotic effect of coagulation factor VIIa. Blood 102:1708–1715
18. Aberg M, Johnell M, Wickstrom M, Siegbahn A (2011) Tissue Factor/FVIIa prevents the extrinsic pathway of apoptosis by
regulation of the tumor suppressor Death-Associated Protein Kinase 1 (DAPK1). ThrombRes 127:141–148
19. Yuan X, Gajan A, Chu Q, Xiong H, Wu K, Wu GS (2018) Developing TRAIL/TRAIL death receptor-based cancer therapies. Cancer Metastasis Rev 37:733–748
20. Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM (1997) An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 277:815–818
21. Sato K, Niessner A, Kopecky SL, Frye RL, Goronzy JJ, Weyand CM (2006) TRAIL-expressing T cells induce apoptosis of vascular smooth muscle cells in the atherosclerotic plaque. JExpMed 203:239–250
22. Osher E, Macaulay VM. (2019) Therapeutic Targeting of the IGF Axis. Cells 8.
23. Zhao D, Bakirtzi K, Zhan Y, Zeng H, Koon HW, Pothoulakis C (2011) Insulin-like growth factor-1 receptor transactivation modulates the inflammatory and proliferative responses of neurotensin in human colonic epithelial cells. JBiolChem 286:6092–6099
24. Aberg M, Eriksson O, Mokhtarri D, Siegbahn A (2014) Tissue factor/factor VIIa induces cell survival and gene transcription by transactivation of the insulin-like growth factor I receptor. Thromb Haemost 111:748–760
25. Sevinsky JR, Rao LV, Ruf W (1996) Ligand-induced protease receptor translocation into caveolae: a mechanism for regulating cell surface proteolysis of the tissue factor-dependent coagulation pathway. J Cell Biol 133:293–304
26. Awasthi V, Mandal SK, Papanna V, Rao LV, Pendurthi UR (2007) Modulation of tissue factor-factor VIIa signaling by lipid rafts and caveolae. Arterioscler Thromb Vasc Biol 27:1447–1455
27. Huo H, Guo X, Hong S, Jiang M, Liu X, Liao K (2003) Lipid rafts/caveolae are essential for insulin-like growth factor-1 receptor signaling during 3T3-L1 preadipocyte differentiation induction. The Journal of biological chemistry 278:11561–11569
28. de Laurentiis A, Donovan L, Arcaro A (2007) Lipid rafts and caveolae in signaling by growth factor receptors. Open Biochem J 1:12–32
29. Li S, Couet J, Lisanti MP (1996) Src tyrosine kinases, Galpha subunits, and H-Ras share a common membrane-anchored scaffolding protein, caveolin. Caveolin binding negatively regulates the auto-activation of Src tyrosine kinases. The Journal of biological chemistry 271:29182–29190
30. Couet J, Li S, Okamoto T, Ikezu T, Lisanti MP (1997) Identification of peptide and protein ligands for the caveolin-scaffolding domain. Implications for the interaction of caveolin with caveolae-associated proteins. The Journal of biological chemistry 272:6525–6533
31. Bucci M, Gratom JP, Rudic RD et al (2000) In vivo delivery of the caveolin-1 scaffolding domain inhibits nitric oxide synthesis and reduces inflammation. Nat Med 6:1362–1367
32. Malarstig A, Tenno T, Jossan S, Aberg M, Siegbahn A (2003) A quantitative real-time PCR method for tissue factor mRNA. Thromb Res 112:175–183
33. Blokzijl A, Friedman M, Ponten F, Landegren U (2010) Profiling protein expression and interactions: proximity ligation as a tool for personalized medicine. J Intern Med 268:232–245
34. Zatloukal B, Kufferath I, Thueringer A, Landegren U, Zatloukal K, Haybueck J (2014) Specificity and sensitivity of in situ proximity ligation for protein interaction analysis in a model of steato-hepatitis with Mallory-Denk bodies. PLoS ONE 9:e96690
35. Hailstones D, Sleer LS, Parton RG, Stanley KK (1998) Regulation of caveolin and caveole by cholesterol in MDCK cells. J Lipid Res 39:369–379
36. Sanguinetti AR, Mastick CC (2003) c-Ab1 is required for oxidative stress-induced phosphorylation of caveolin-1 on tyrosine 14. Cell Signal 15:289–298
37. Li S, Seitz R, Lisanti MP (1996) Phosphorylation of caveolin by src tyrosine kinases. The alpha-isoform of caveolin is selectively phosphorylated by v-Src in vivo. The Journal of biological chemistry 271:3863–3868
38. Wiiger MT, Prydz H (2004) The epidermal growth factor receptor (EGFR) and proline rich tyrosine kinase 2 (PYK2) are involved in tissue factor dependent VIIa signalling in HaCaT cells. Thromb Haemost 92:13–22
39. Siegbahn A, Johnell M, Nordin A, Aberg M, Velling T (2008) TFP/VIIa transactivates PDGFRbeta to regulate PDGF-BB-induced chemotaxis in different cell types: involvement of Src and PLC. Arterioscler Thromb Vasc Biol 28:135–141
40. Park CC, Zhang H, Pallavicini M et al (2006) Betax integrin inhibitory antibody induces apoptosis of breast cancer cells, inhibits growth, and distinguishes malignant from normal phenotype in three dimensional cultures and in vivo. Cancer Res 66:1526–1535
41. Zhang K, Ding W, Sun W et al (2016) Beta1 integrin inhibits apoptosis induced by cyclic stretch in annulus fibrosus cells via ERK1/2 MAPK pathway. Apoptosis 21:13–24
42. Couet J, Sargiacomo M, Lisanti MP (1997) Interaction of a receptor tyrosine kinase, EGF-R, with caveolins. Caveolin binding negatively regulates tyrosine and serine/threonine kinase activities. The Journal of biological chemistry 272:30429–30438
43. Yamamoto M, Toya Y, Jensen RA, Ishikawa Y (1999) Caveolin is an inhibitor of platelet-derived growth factor receptor signaling. Exp Cell Res 247:380–388
44. Razani B, Zhang XL, Bitter M, von Gersдорff G, Bottinger EP, Lisanti MP (2001) Caveolin-1 regulates transforming growth factor (TGF)-beta/SMAD signaling through an interaction with the TGF-beta type I receptor. The Journal of biological chemistry 276:6767–6773
45. Bilderback TR, Gazula VR, Lisanti MP, Dobrowsky RT (1999) Caveolin interacts with Trk A and p75(NTR) and regulates neurotrophin signaling pathways. The Journal of biological chemistry 274:257–263
46. Williams TM, Medina F, Badano I et al (2004) Caveolin-1 gene disruption promotes mammary tumorigenesis and dramatically enhances lung metastasis in vivo. Role of Cav-1 in cell invasiveness and matrix metalloproteinase (MMP-2/9) secretion. The Journal of biological chemistry 279:51630–51646
47. Salani B, Briatore L, Garibaldi S, Cordera R, Maggi D (2008) Caveolin-1 down-regulation inhibits insulin-like growth factor-I receptor signal transduction in H9C2 rat cardiomyoblasts. Endocrinology 149:461–465
48. Tang W, Feng X, Zhang S et al (2015) Caveolin-1 Confers Resistance of Hepatoma Cells to Anoikis by Activating IGF-1 Pathway. Cell Physiol Biochem 36:1223–1236
49. Maggi D, Biedi C, Segat D, Barbero D, Panetta D, Cordera R (2002) IGF-I induces caveolin 1 tyrosine phosphorylation and translocation in the lipid rafts. Biochem Biophys Res Commun 295:1085–1089
50. Moro L, Dolce L, Cabodi S et al (2002) Integrin-induced epithelial growth factor (EGF) receptor activation requires c-Src and p130Cas and leads to phosphorylation of specific EGFR receptor tyrosines. The Journal of biological chemistry 277:9405–9414
51. Qu X, Wu Z, Dong W et al (2017) Update of IGF-1 receptor inhibitor (ganimub, dalatuzumub, cixutumubub, teprotumubub and figitumubub) effects on cancer therapy. Oncotarget 8:29501–29518
52. Casalotto JB, McClatchey AI (2012) Spatial regulation of recep-
ar tyrosine kinase, EGF-R, with caveolins. Caveo-
53. Tecchio C, Huber V, Scapini P et al (2004) IFNalpha-stimulated neutrophils and monocytes release a soluble form of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) displaying apoptotic activity on leukemic cells. Blood 103:3837–3844
54. Eden D, Siegbahn A, Mokhtari D (2015) Tissue factor/factor VIIa signalling promotes cytokine-induced beta cell death and impairs glucose-stimulated insulin secretion from human pancreatic islets. Diabetologia 58:2563–2572

55. Ethaeb AM, Mohammad MA, Madkhali Y, et al. (2019) Accumulation of tissue factor in endothelial cells promotes cellular apoptosis through over-activation of Src1 and involves beta1-integrin signalling. Apoptosis.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.